1. Introduction {#sec1}
===============

Oral cancer is one of the ten most common cancers worldwide. Nearly 3% of all cancer cases are oral cancers; they are more common in men than in women; and two-thirds of oral cancer cases occur in developing countries \[[@B1], [@B2]\]. One important hallmark of cancer progression is the degradation of the extracellular matrix (ECM), which allows cancer cells to invade the surrounding tissue. Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that efficiently degrade the components of the ECM and basement membranes (BM). MMPs also release cytokines, chemokines, and growth factors from their proforms or their cryptic sites \[[@B3]--[@B6]\]. To date, at least 24 distinct MMP genes have been identified in humans. MMPs are classified according to their substrate specificities: gelatinases, collagenases, matrilysins, and stromelysins. The structures of all MMPs include an N-terminal signal peptide that directs the protein to either the plasma membrane insertion or to the secretory pathway; its prodomain confers its latency, and its catalytic domain has a zinc atom in its active site. MMPs are either anchored in the membrane or secreted, primarily as latent proforms that require activation before becoming catalytically competent \[[@B7]--[@B9]\]. Two different soluble gelatinases have been identified: gelatinase A, 72 kDa (MMP-2), and gelatinase B, 92 kDa (MMP-9). Both contain a collagen-binding domain within their catalytic domain, distinguishing them from other MMPs. A more detailed structure of these enzymes is described in a review by Björklund and Koivunen \[[@B10]\].

2. Activation of MMP-9 {#sec2}
======================

Typically, gelatinases are secreted as inactive zymogens that become activated extracellularly. The most relevant natural activators of proMMP-9 are unknown, but proMMP is activated through a few different mechanisms, including proteolytic activation, where the prodomain is cleaved yielding an active enzyme. Latent MMP-9 can be activated by MMP-3, which cleaves proMMP-9 at multiple sites: the first cleavage site is Glu^59^-Met^60^; the second is Arg^106^-Phe^107^ \[[@B11]\]. In contrast, MMP-26 activates MMP-9 by cleaving at Ala^93^-Met^94^ \[[@B12]\]. Previous studies have also demonstrated that enterokinase, a membrane-bound serine protease, cleaves proMMP-9 at Lys^65^-Ser^66^ \[[@B13]\] and that trypsin-2 activates proMMP-9 at very low molar ratios, 1 : 1000. The peptide bond can also be cleaved at Arg^87^-Phe^88^ \[[@B14]\]. Other known proteolytic activators are plasmin, chymotrypsin-like proteinase, MMP-2, MMP-7, MMP-10, and MMP-13 \[[@B15]--[@B20]\]. There are other identified activation mechanisms for MMP-9: oxidation by reactive oxygen species, S-nitrosylation, and allosteric activation, which occurs when proMMP-9 is bound to either a gelatin or type IV collagen \[[@B21]--[@B23]\]. In an invasive tongue squamous cell carcinoma cell line (HSC-3), MMP-9 is colocalized with trypsin-2 in intracellular vesicles \[[@B13]\]. This intracellular activation may be an alternative activation mechanism for proMMPs in oral cancers. Similar intracellular vesicle transports for MMP-9 are also found in melanoma cells and in ovarian cancer ascites \[[@B24], [@B25]\]. In oral squamous cell carcinoma (OSCC), the activation level of MMP-9 may be associated with a shortened disease-free survival and a high metastatic frequency \[[@B26]\].

3. Inhibitors of MMP-9 {#sec3}
======================

Tissue inhibitors of metalloproteinases (TIMPs) are specific endogenous inhibitors of MMPs, which bind MMPs in a 1 : 1 stoichiometry. Four different TIMPs have been identified: TIMP-1, TIMP-2, TIMP-3, and TIMP-4 \[[@B27]\]; they all inhibit MMP-9 *in vitro*\[[@B28]--[@B31]\]. The role of TIMPs in OSCC is well-studied and is the focus of a recent review by Garćia et al. \[[@B32]\]. After the role of MMPs in cancer invasion and metastasis formation was recognized, researchers began developing synthetic inhibitors. The first generation of peptidomimetic MMPs, batimastat (BB94) and ilomastat (GM-6001), mimicked the structure of collagen and reversibly bound the active site of MMPs to inhibit MMP activity \[[@B33], [@B34]\]. Next, Marimastat (BB-2516), a second generation of MMP inhibitors, was developed. However, all of these broad-spectrum inhibitors failed in clinical trials due to their side effects and their lack of efficacy \[[@B35]--[@B37]\], which led to the development of more selective matrix metalloproteinase inhibitors (MMPIs). We developed the first gelatinase-specific MMPI CTTHWGFTLC peptide, which inhibited the invasion of ovarian carcinoma, breast carcinoma, fibrosarcoma, Kaposi\'s sarcoma, and melanoma cell lines, *in vitro*; it also increased the survival of human tumor xenografts \[[@B38]\]. Since then, we have developed a cyclic gelatinase-specific inhibitor GRENYHGCTTHWGFTLC peptide, which inhibits MMP-9 activation and activity, the growth of human tongue cancer cell xenografts, and angiogenesis in nude mice \[[@B39]\]. The synthetic MMPIs that inhibit MMP-9 are listed in [Table 1](#tab1){ref-type="table"}.

4. MMP-9 in the Oral Microenvironment {#sec4}
=====================================

In addition to carcinoma cells, cancers consist of tumor-associated stromal cells, which include fibroblasts, endothelial cells, leukocytes, macrophages, nerve cells, and adipocytes. During cancer progression, the cancer cells crosstalk with stromal components and their interactions are partially mediated by transmembrane receptors, which are expressed on cancer cells and stromal cells. Tumor-associated cells promote angiogenesis, inflammation, invasion, and ECM modeling through cell-cell contact and the production of growth factors, hormones, cytokines, and proteinases such as MMPs \[[@B40]--[@B42]\]. In OSCC tumors, MMP-9 is expressed in carcinoma and inflammatory cells around carcinoma islands. Meanwhile, MMP-2 is mainly found in carcinoma-associated fibroblasts (CAFs) \[[@B43], [@B44]\]. In an oral squamous cell carcinoma cell line SCC-25, CAFs increase the expression of MMP-9, *in vitro*, which is thought to occur via a fibronectin-integrin *α*v*β*6 pathway \[[@B45]\]. In the aggressive human tongue squamous cell carcinoma cell line HSC-3, MMP-2 was only found in its latent form, whereas MMP-9 was found in its active form \[[@B13]\]. MMP-9′s effect during HSC-3 cell line invasion was studied in a human organotypic model based on myoma tissue \[[@B46]\], which contains fibroblasts, smooth muscle cells, lymphocytes, macrophages, endothelial cells, and MMP-2, but not MMP-9 \[[@B46]\]. Therefore, this model is a better predictor of the *in vivo* tumor microenvironment compared with the commonly used rat tail-derived type I collagen and/or the mouse EHS sarcoma-derived Matrigel invasion assay. In the myoma organotypic invasion assay, after inhibiting gelatinase activity in HSC-3 cells using a specific gelatinase inhibitor CTTHWGFTLC \[[@B38]\], the tumor cells were surprisingly more invasive than in the control group (unpublished data). Mice bearing HSC-3 xenograft tumors treated with the gelatinase inhibitor CTTHWGFTLC had smaller primary tumors *in vivo* than the control group \[[@B39]\], but the inhibition of gelatinases did not affect local invasion or metastasis formation \[[@B47]\]. The ability of cancer cells to change their migration under certain circumstances from proteolytic to non-proteolytic, amoeboid type during protease-inhibitor treatment helps to explain the OSCC behaviors we observed. Thus, these cells change their shape and adapt to squeeze through tissue gaps without degrading the ECM \[[@B48]\]. MMP-9 may not be the only, or even the most important, proteolytic enzyme in the OSCC invasion process, but it may be important for indirect cell signaling by controlling the bioavailability and bioactivity of molecules that target specific receptors, which regulate cell growth, migration, inflammation, and angiogenesis \[[@B49]--[@B53]\].

5. The Role of MMP-9 in OSCC Invasion and Metastasis {#sec5}
====================================================

MMP-9 is associated with the aggressive nature of many cancers, including OSCC \[[@B54]--[@B57]\], and this aggressive nature was thought to cause type IV collagen degradation, a main component of basement membranes \[[@B58]\]. To date, the spectrum of MMP-9 matrix substrates has significantly increased, and aside from substrates, which originate in the matrix, MMP-9 has other bioactive substrates that independently modulate carcinogenesis, such as the pro-transforming growth factor-*β*1 (TGF-*β*1) and the pro-tumor necrosis factor-*α* (TNF-*α*) \[[@B10], [@B59], [@B60]\]. MMP-9 has traditionally been associated with the aggressive nature of OSCC. However, in spite of increased MMP-9 expression levels, many researchers have presented contradictory results \[[@B61]--[@B63]\] ([Table 2](#tab2){ref-type="table"}). For example, Guttman et al. \[[@B64]\] did not find a correlation between MMP-9 expression and the size of the primary tumor or the neck metastasis in tongue SCC patients. Meanwhile, another study reported that high levels of MMP-9 expression in OSCC patients were correlated with regional lymph node and/or distant metastases and a poor prognosis \[[@B65]\]. In addition, De Vicente et al. \[[@B66]\] showed that MMP-9 expression was not associated with clinical variables, such as tumor stage or recurrence rate. In a study conducted by Ikebe et al., gelatinolytic activity and increased expression of both MMP-2 and MMP-9 in OSCC tumors were related to the invasiveness, but not to the metastatic potential of OSCC tumors \[[@B67]\]. Finally, Kato and co-workers \[[@B68]\] showed that, although MMP-9 expression was high in OSCCs, the activated form:proform ratio was very low, while activated MMP-2s were elevated and associated with advanced stages of disease. These findings suggest that MMP-9 may not be a universal cancer progression promotion factor in OSCCs; instead, it may have fluctuating roles.

6. MMP-9 in the Modulation of Cancer-Related Inflammation {#sec6}
=========================================================

Chronic inflammation is associated with epithelial cancers, and it differs from normal inflammation because it is not self-limiting. Cancer cells produce different cytokines that attract innate immune cells, such as mast cells, granulocytes, and macrophages. These innate immune cells then secrete interleukins, chemokines, reactive oxygen species, and MMPs that modulate angiogenesis, cell proliferation, tumor growth, and invasion \[[@B69]--[@B71]\]. In OSCCs, the level of a multifunctional cytokine, transforming growth factor-*β*1, is upregulated, which leads to the enhanced expression of snail. Snail is a transcription factor that increases MMP-9 expression and triggers an epithelial-mesenchymal transition (EMT); then, carcinoma cells change their morphology, reduce their intercellular and cell-matrix adhesions, and increase their motility \[[@B72], [@B73]\]. Interestingly, the inactive form of TGF-*β*1 is activated by MMP-9 \[[@B74]\]. Many other cytokines are also substrates for MMP-9, including TNF-*α*, CXCL1, CXCL4, CXCL7, CXCL8, and interleukin-1*β* \[[@B49]--[@B51]\]. Interleukin-1*β* is secreted by tumor cells and induces the expression of lipocalin 2 \[[@B75], [@B76]\]. The plasma levels of lipocalin 2, MMP-9 and the lipocalin 2/MMP-9 complex are associated with more advanced clinical stages and/or tumor sizes in OSCC patients. Interestingly, MMP-9 levels are not correlated with either lymph nodes or distant metastases \[[@B77]\]. Chemokine CXCL8 can induce the release of MMP-9 from tertiary neutrophil granules, and increased CXCL8 expression is associated with OSCC. The CXCL8 expressed in tumor cells is also secreted by OSCC cell lines, and CXCL8 mRNA expression is enhanced by the addition of TNF-*α* and IL- 1*β*. CXCL8 from OSCC cell lines increases cell migration, induces invasion, and increases the expression of MMP-7. However, it does not have an effect on MMP-9 expression. Therefore, CXCL8-induced expression of MMP-9 may be cell-type specific \[[@B78]--[@B80]\]. The chemokine receptor, CXCR4, modulates the invasion of OSCCs by regulating MMP-9 expression. In patients, this expression correlates with lymph node metastasis and MMP-9 expression \[[@B81], [@B82]\]. Cyclo-oxygenase (COX)-2 is an enzyme that converts arachidonic acid into pro-inflammatory prostanoids. COX-2 has been implicated in carcinogenesis and its mRNA expression is nearly 150-fold greater in head and neck squamous cell carcinomas compared with normal oral mucosa. Using a selective COX-2 inhibitor decreases MMP-9 and MMP-2 expression and suppresses the proliferation and invasion of OSCCs \[[@B83], [@B84]\]. In fact, MMP-9 has many links to the cancer-related inflammation observed in OSCCs, but MMP-9′s specific role in this process remains unclear.

7. MMP-9 in the Regulation of Angiogenesis {#sec7}
==========================================

Low oxygen levels, or hypoxia, are typical in solid tumors that grow 1-2 mm^3^ without vascularization. Angiogenesis, the formation of new blood vessels, is required to bring nutrition and oxygen to cells, remove metabolic waste, and support larger tumor growth. Not only is angiogenesis associated with tumor growth, it is also related to the development of metastases in OSCCs \[[@B85]--[@B89]\]. This process is initiated by vascular endothelial growth factor (VEGF), an angiogenic cytokine. The effect of VEGF is mediated by vascular endothelial growth factor receptors. The hypoxic conditions stabilize hypoxia-inducible factors (HIFs) that bind to the VEGF promoter, which causes upregulation of VEGF and increases the expression of VEGFR-receptor-1 in endothelial cells, cancer cells and tumor-associated cells, such as macrophages \[[@B87], [@B90]--[@B93]\]. In OSCCs, overexpression of HIF-1*α* is associated with a poor patient outcome \[[@B94]\]. Increased tumor hypoxia is also associated with increased MMP-2 and MMP-9 activity \[[@B95]\].

The regulation of angiogenesis is a very delicate balance between pro- and antiangiogenic factors, and it seems that MMP-9 plays a dual role in this process. It can act as a proangiogenic factor via VEGF regulation; as Hiratsuka et al. \[[@B96]\] demonstrated, primary tumors in premetastatic lungs induce MMP-9 expression in a VEGFR-1-dependent manner, which enhances the invasion of cancer cells and facilitates metastasis. MMP-9 also triggers the angiogenic switch by releasing VEGF \[[@B60]\]. MMP-9 and VEGF are expressed during invasive OSCCs of the tongue and in metastatic tumors that tend to express higher levels of VEGF and MMP-9, than nonmetastatic tumors \[[@B97]\]. In another study, increased VEGF expression was associated with a poor prognosis in OSCC patients, whereas MMP-9 expression levels had no correlation with patient outcomes \[[@B98]\]. This can be explained by the antiangiogenic role of MMP-9, which causes cleavage of type XVIII collagen, and leads to the release of endostatin, a potent inhibitor of angiogenesis and endothelial cell migration \[[@B52], [@B53]\]. OSCC primary tumors that do not metastasize have high endostatin levels compared with primary tumors that are associated with multiple metastatic lymph nodes. Full-length collagen XVIII expression levels are decreased in aggressive tumors \[[@B99]\]. Based on our study \[[@B100]\], collagen XVIII was expressed in mild oral epithelial dysplasias but was absent in the invasive fronts of OSCCs. Although MMP-9 expression was observed in these same samples, there was no correlation between MMP-9 and the stage of disease. Homer et al. \[[@B101]\] reported that in head and neck squamous cell carcinoma, the plasma levels of endostatin may predict tumor recurrence. Collagen XVIII and VEGF are both expressed at the same time in OSCCs, which further demonstrates that modulation of angiogenesis requires a delicate balance between angiogenic inhibitors and stimulators \[[@B91]\]. Moreover, we have demonstrated that endostatin also directly inhibits the invasion and intravasation of a human tongue SCC cell line and blocks the activity of proMMP-9, suggesting a feedback loop for MMP-9 regulation \[[@B102]\]. When mice bearing nasopharyngeal carcinoma tumors were treated with endostar (recombinant endostatin), the treatment led to a significant decrease in MMP-9 and VEGF expression levels and normalized the tumor vasculature \[[@B103]\]. Endostatin was not the only cryptic angiogenesis inhibitor liberated by MMP-9. Angiostatin, a fragment of plasminogen, also inhibits endothelial cell proliferation \[[@B59], [@B104]\]. Pozzi et al. \[[@B105]\] proved that decreased MMP-9 plasma levels in tumor-bearing mice also decreases angiostatin levels, which increases tumor vascularization and growth. Matsumoto et al. \[[@B106]\] observed that angiostatin-overexpressing SCC tumors in mice grew slower than the control tumors. Aside from endostatin and angiostatin production, MMP-9 is also associated with the proteolytic degradation of type IV collagen, which produces an angiogenesis inhibitor, tumstatin \[[@B107], [@B108]\]. These findings suggest that in cancer angiogenesis the variations in spatial and temporal MMP-9 expression may switch between two roles: from a proangiogenic to an antiangiogenic molecule ([Figure 1](#fig1){ref-type="fig"}).

8. Effect of Genetic and Environmental Factors on the Expression of MMP-9 {#sec8}
=========================================================================

The development and progression of OSCCs are a result of interactions between accumulating genetic alterations and environmental factors, such as alcohol, tobacco, viral infection, or chronic inflammation \[[@B109]\]. Despite newer cancer treatments, approximately 50% of patients die within 5 years of diagnosis \[[@B110]\]. This can be partially explained by the theory of oral field cancerization: an oral mucosa exposed to carcinogens, such as alcohol, causes multiple genetic abnormalities in the entire epithelium and increases the risk of developing several dysplastic lesions \[[@B111]\]. Polymorphisms in the *MMP9* gene allele are associated with an increased risk of developing the initial stages of oral cancer among patients without a family history of cancer and high smoking and/or alcohol use \[[@B112]\]. MMP-9 expression did not correlate with age, gender, tumor location, or smoking habits, whereas an association with tumor grade differentiation and alcohol consumption was observed \[[@B66]\]. MMP-9 was not expressed in the normal oral mucosa or dysplasia, whereas *in situ* carcinomas were weakly detectable. In OSCC, it was expressed in the same areas where collagen (IV) chain loss was observed at the invasive fronts, whereas in other studies, its overexpression was detected in 85% of oral dysplasias and in all of the oral cancer samples. The mRNA levels of MMP-9 were higher in oral dysplasia that progressed to oral SCC \[[@B113], [@B114]\]. Ogbureke et al. 2012 \[[@B115]\] proposed that MMP-9 expression at histologically negative surgical margins could predict OSCC recurrence. Interestingly, MMP-9 was absent from the margins of tumors ≤4 cm and only 10% of tumors without later node metastasis expressed it. MMP-9 expression alternates between different stages of malignant transformations. Different clinicopathological variables in OSCCs can partially be explained by viral infections in epithelial cells. The human papilloma virus (HPV) is associated with OSCCs, especially type 16. HPV16 transgenic mice, HPV16/MMP-9 +/+ and HPV16/MMP-9 +/− develop a similar incidence of SCC after 12 months of age, whereas HPV16/MMP-9 −/− mice have fewer tumors, but these tumors were more poorly differentiated than those in the other groups. The expression of HPV16 oncoproteins in human keratinocytes induced the upregulation of MMP-9 activity. At the same time, two natural MMP inhibitors were downregulated. One of them was the reversion-inducing cysteine-rich protein with Kazal motifs (RECK), which affects transcription, synthesis, activation, and the activity of MMPs; the other was TIMP-2 \[[@B116]--[@B118]\]. HPV16 infection may be one mechanism behind the contradictory expression of MMP-9 in OSCC patients; however, further studies are necessary to understand its significance.

9. Methods for MMP-9 Investigation in Oral Cancer {#sec9}
=================================================

The most commonly used immunohistological analyses of MMP-9 expression can be misleading because most antibodies do not distinguish between the pro- and active forms of the protein. The total amount of protein expression does not necessarily mean that the enzyme is in an active form \[[@B119]\]. Gelatin zymography or *in situ* zymography \[[@B120], [@B121]\] are better methods to evaluate the level of gelatinase activity and would have provided more information in the studies referred to here ([Table 2](#tab2){ref-type="table"}) \[[@B121]\]. Many other techniques can investigate the presence, amount and function of MMP-9. For example, *in situ* hybridization could define the location and number of cells that express MMP-9 mRNA in tissue sections, whereas the polymerase chain reaction (PCR) could detect the presence and amount of mRNA in tissues or cell extracts \[[@B122], [@B123]\]. More specific intracellular localization of MMP-9 could easily be achieved using confocal laser scanning microscopy, which enables a 3-dimensional definition of protein localization \[[@B13]\]. Enzyme-linked immunosorbent assays (ELISAs) could be used to determine the concentration of MMP-9 protein in serum and plasma samples; based on these studies, MMP-9 is a systemic biomarker that monitors the effectiveness of OSCC treatment \[[@B94], [@B123], [@B124]\]. Different blotting methods, Western, Northern, and Southern, reveal the expression of protein, RNA or DNA, respectively, in various samples \[[@B67], [@B125]\]. MMPIs, transfected cell lines, and knock-out animal models give more functional data about MMP-9 \[[@B126], [@B127]\]. Most likely, the variety of methodologies and the low sample sizes explain the high variation observed among the previous OSCC results. Therefore, more studies with larger well-documented clinical materials, using delicate methods, are necessary to determine the impact of MMP-9 in OSCC.

10. Conclusions {#sec10}
===============

Generally MMP-9 has been associated with aggressive head and neck cancers, but novel studies have shown that it acts as a protective molecule during carcinogenesis and metastasis. For example, in salivary gland myoepithelial carcinoma, MMP-9 expression predicts a better overall survival, and in regional metastases of head and neck cancers, *MMP9* gene expression was decreased \[[@B128], [@B129]\]. Similarly, the expression of MMP-9 is associated with a better outcome in breast- and colitis-associated carcinomas \[[@B130], [@B131]\]. Additionally, in oral cancer the role of MMP-9 was purely associated with the degradation of the ECM, which led to the enhancement of carcinoma cell invasion. However, the philosophy of oral carcinoma progression has become significantly more complicated; now, MMP-9 is known as a multifunctional modulator that is involved in very complex cell-signaling cascades ([Figure 2](#fig2){ref-type="fig"}). Therefore, in the case of MMP-9, one reason for the obvious failures of broad-spectrum and specific MMPIs in cancer treatment might be due to its fluctuating role in cancer, which not only affects carcinoma cells but also other cell populations. The tumor microenvironment matrix expresses and sequesters MMP-9. Taken together, our current knowledge of MMP-9 has been extended; it can act as either a carcinoma protector or promoter depending on the specific situation, which is related to patient characteristics, including the stage, grade, and location of the tumor.
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![Effect of MMP-9 on angiogenesis in oral cancer. MMP-9 inhibits angiogenesis by releasing antiangiogenic factors from their precursors. MMP-9 enhances angiogenesis by releasing and activating VEGF from extracellular proteoglycans.](TSWJ2013-920595.001){#fig1}

![Schematic picture of the events that are modulated by MMP-9 in oral cancer. Proteolytic degradation of ECM components (including types III, IV, and V collagens, as well as gelatin) by MMP-9 facilitates carcinoma cell invasion and leads to the release of growth factors, such as VEGF, that enhance angiogenesis and tumor progression. At the same time anti-antiangiogenic endostatin, angiostatin, and tumstatin are released. Processing of proinflammatory chemokines (CXCL1, -4, -8, -9, -11, -12), proforms of cytokines (proTNF-*α*, proIL-1*β*), cell adhesion proteins such as intercellular adhesion molecule-1 triggers an inflammatory reaction and modulates transcription factors leading to an epithelial-to-mesenchymal transition and enhanced carcinogenesis.](TSWJ2013-920595.002){#fig2}

###### 

Synthetic MMP-9 inhibitors.

  Name                Type of drug                           Specifity of the inhibition        Reference
  ------------------- -------------------------------------- ---------------------------------- -------------
  Batimastat          Peptidomimetic                         MMP-1, -2, -3, -7, -9              \[[@B132]\]
  Marimastat          Peptidomimetic                         Broad spectrum                     \[[@B133]\]
  CTTHWGFTLC          Peptidomimetic                         MMP-2, -9                          \[[@B38]\]
  CGYGRFSPPC          Peptidomimetic                         MMP-2, -9                          \[[@B134]\]
  CRVYGPYLLC          Peptidomimetic                         MMP-2, -9                          \[[@B134]\]
  ABT-518             Peptidomimetic                         MMP-2, -9                          \[[@B135]\]
  GRENYHGCTTHWGFTLC   Peptidomimetic                         MMP-2, -9                          \[[@B39]\]
  Ilomastat           Peptidomimetic                         Broad spectrum                     \[[@B136]\]
  Tanovastat          Nonpeptidomimetic                      MMP-2, -3, -9                      \[[@B137]\]
  Prinovastat         Nonpeptidomimetic                      MMP-2, -3, -7, -9, -13             \[[@B138]\]
  BMS-275291          Nonpeptidomimetic                      MMP-2, -9                          \[[@B139]\]
  Metastat (COL-3)    Chemically modified tetracycline       MMP-1, -2, -8, -9, -13             \[[@B140]\]
  CMT-3               Chemically modified tetracycline       MMP-8, -9, -MT1-MMP                \[[@B141]\]
  Doxycycline         Chemically modified tetracycline       MMP-1, -2, -3, -8, -9, -10, -13    \[[@B142]\]
  SB-3CT              Reform proenzyme structure             MMP-2, -9                          \[[@B143]\]
  Bisphosphonates     Analogues of inorganic pyrophosphate   MMP-1, -2, -7, -9, MT1-, MT2-MMP   \[[@B144]\]
  Chlorhexidine       Bisbiguanide antiseptic                MMP-2, -8, -9                      \[[@B145]\]
  Letrozole           Nonsteroidal inhibitor of aromatase    MMP-2, -9                          \[[@B146]\]
  PCK 3145            Synthetic peptide based on PSP94       MMP-9                              \[[@B147]\]

###### 

MMP-9 expression in oral cancer.

  MMP-9 expression   Sample type   Lymph node metastasis   Outcome                      MMP-9 activity   Method                                                   Number of cases   References
  ------------------ ------------- ----------------------- ---------------------------- ---------------- -------------------------------------------------------- ----------------- -------------
  High               Tissue        Yes                     \*                           \*               Immunohistochemistry                                     96                \[[@B61]\]
  Yes                Tissue        Yes                     \*                           \*               Immunohistochemistry                                     61                \[[@B62]\]
  High               Tissue        \*                      Shortened disease survival   High             Gelatin zymography,                                      44                \[[@B63]\]
  Yes                Tissue        No                      nc                           \*               Immunohistochemistry                                     23                \[[@B64]\]
  High               Tissue        Yes                     Poor                         \*               Immunohistochemistry                                     53                \[[@B65]\]
  High               Tissue        No                      \*                           High             Gelatin zymography, immunohistochemistry, western blot   57                \[[@B67]\]
  High               Tissue        \*                      \*                           Low              Immunohistochemistry, gelatin zymography,                31                \[[@B68]\]
  High               Plasma        No                      \*                           \*               ELISA                                                    195               \[[@B77]\]
  Yes                Tissue        No                      nc                           \*               Immunohistochemistry                                     68                \[[@B66]\]
  High               Tissue        \*                      Better survival              \*               Immunohistochemistry                                     12                \[[@B128]\]
  High               Tissue        Yes                     Shortened disease survival   \*               Immunohistochemistry                                     48                \[[@B148]\]

\*not studied, nc: no correlation.

[^1]: Academic Editors: S. Bhan, A. Chuang, and J. E. J. Lee
